<DOC>
	<DOCNO>NCT02306694</DOCNO>
	<brief_summary>One major shortcoming study bone disease hemophilia lack fracture outcome data demonstrate clinical significance decrease BMD alter bone biomarkers hemophilia population . This study demonstrate PwH increase risk fracture compare general population issue bone health increase importance PwH population age .</brief_summary>
	<brief_title>Prospective Biomarkers Bone Metabolism Hemophilia A</brief_title>
	<detailed_description>This pilot study determine impact factor replacement bone biomarkers 20 hemophilia A subject . Subjects recruit 1 year 5-day protocol . Following 72-hour washout period , factor level bone biomarkers follow 50 units/kg replacement Day 1 20 units/kg replacement Day 3 . Each subject serve Figure 4 . Fracture rate PwH compare historic control .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Males diagnosis hemophilia A historic baseline FVIII level â‰¤ 2 % . 2 . Age &gt; 16 year old 3 . Currently use ADVATE FVIII replacement therapy 1 . Subject guardian unwilling unable give write informed consent and/or assent 2 . Joint muscle bleed within 2 week Study Day 1 3 . Presence current factor inhibitor ( &gt; 0.6 BU/mL via Nijmeganmodified Bethesda assay ) 4 . Known collagen vascular bone disease .</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hemophilia</keyword>
	<keyword>bone disease</keyword>
	<keyword>clinical study</keyword>
	<keyword>biomarkers</keyword>
</DOC>